{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:38:52Z","timestamp":1792291132372,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2019,3,15]]},"DOI":"10.1007\/s00380-018-1270-x","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T05:16:31Z","timestamp":1537938991000},"page":"442-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR"],"prefix":"10.1007","volume":"34","clinical-trial-number":[{"clinical-trial-number":"umin000009201","registry":"10.18810\/umin-japan"}],"author":[{"given":"Yuki","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Inomata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Shibagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Kanagawa Aquaresis Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,26]]},"reference":[{"key":"1270_CR1","doi-asserted-by":"publisher","first-page":"165a","DOI":"10.1016\/0735-1097(93)90484-I","volume":"22","author":"RJ Cody","year":"1993","unstructured":"Cody RJ (1993) Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. J Am Coll Cardiol 22:165a\u2013171a","journal-title":"J Am Coll Cardiol"},{"key":"1270_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10741-012-9354-7","volume":"19","author":"L Leto","year":"2014","unstructured":"Leto L, Aspromonte N, Feola M (2014) Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review. Heart Fail Rev 19:237\u2013246","journal-title":"Heart Fail Rev"},{"key":"1270_CR3","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ejheart.2007.07.011","volume":"9","author":"V Hasselblad","year":"2007","unstructured":"Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF Jr (2007) Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 9:1064\u20131069","journal-title":"Eur J Heart Fail"},{"key":"1270_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/eurheartj\/ehu065","volume":"35","author":"MA Valente","year":"2014","unstructured":"Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL (2014) Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 35:1284\u20131293","journal-title":"Eur Heart J"},{"key":"1270_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ahj.2015.05.003","volume":"170","author":"JM ter Maaten","year":"2015","unstructured":"ter Maaten JM, Dunning AM, Valente MA, Damman K, Ezekowitz JA, Califf RM, Starling RC, van der Meer P, O'Connor CM, Schulte PJ, Testani JM, Hernandez AF, Tang WH, Voors AA (2015) Diuretic response in acute heart failure\u2014an analysis from ASCEND-HF. Am Heart J 170:313\u2013321","journal-title":"Am Heart J"},{"key":"1270_CR6","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.170","volume":"16","author":"AA Voors","year":"2014","unstructured":"Voors AA, Davison BA, Teerlink JR, Felker GM, Cotter G, Filippatos G, Greenberg BH, Pang PS, Levin B, Hua TA, Severin T, Ponikowski P, Metra M, Investigators RELAX-AHF (2014) Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome\u2014an analysis from RELAX-AHF. Eur J Heart Fail 16:1230\u20131240","journal-title":"Eur J Heart Fail"},{"key":"1270_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrcardio.2014.215","volume":"12","author":"JM ter Maaten","year":"2015","unstructured":"ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors AA (2015) Diuretic response in acute heart failure\u2014pathophysiology, evaluation, and therapy. Nat Rev Cardiol 12:184\u2013192","journal-title":"Nat Rev Cardiol"},{"key":"1270_CR8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1253\/circj.CJ-17-0311","volume":"81","author":"SI Momomura","year":"2017","unstructured":"Momomura SI (2017) Tolvaptan. Is it a trump to worsening renal function? Circ J 81:642\u2013644","journal-title":"Circ J"},{"key":"1270_CR9","first-page":"977","volume":"5","author":"SA Doggrell","year":"2004","unstructured":"Doggrell SA (2004) Tolvaptan (Otsuka). Curr Opin Investig Drugs 5:977\u2013983","journal-title":"Curr Opin Investig Drugs"},{"key":"1270_CR10","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297:1332\u20131343","journal-title":"JAMA"},{"key":"1270_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","volume":"82","author":"T Inomata","year":"2017","unstructured":"Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, Shinagawa H, Ako J, Izumi T, Investigators Kanagawa Aquaresis (2017) Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment\u2014results from the K-STAR study. Circ J 82:159\u2013167","journal-title":"Circ J"},{"key":"1270_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1161\/CIRCHEARTFAILURE.113.000895","volume":"7","author":"JM Testani","year":"2014","unstructured":"Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, Tang WH (2014) Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 7:261\u2013270","journal-title":"Circ Heart Fail"},{"key":"1270_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R (2013) Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients\u2014association between non-responders and chronic kidney disease. Circ J 77:397\u2013404","journal-title":"Circ J"},{"key":"1270_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40256-015-0121-8","volume":"15","author":"D Okayama","year":"2015","unstructured":"Okayama D, Suzuki T, Shiga T, Minami Y, Tsuruoka S, Hagiwara N (2015) Blood urea nitrogen\/creatinine ratio and response to tolvaptan in patients with decompensated heart failure: a retrospective analysis. Am J Cardiovasc Drugs 15:289\u2013293","journal-title":"Am J Cardiovasc Drugs"},{"key":"1270_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jacc.2011.01.054","volume":"58","author":"J Lindenfeld","year":"2011","unstructured":"Lindenfeld J, Schrier RW (2011) Blood urea nitrogen a marker for adverse effects of loop diuretics? J Am Coll Cardiol 58:383\u2013385","journal-title":"J Am Coll Cardiol"},{"key":"1270_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","volume":"25","author":"T Miyazaki","year":"2007","unstructured":"Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T (2007) Tolvaptan, an orally active vasopressin V(2)-receptor antagonist\u2014pharmacology and clinical trials. Cardiovasc Drug Rev 25:1\u201313","journal-title":"Cardiovasc Drug Rev"},{"key":"1270_CR17","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1517\/14656566.2011.567267","volume":"12","author":"A Ambrosy","year":"2011","unstructured":"Ambrosy A, Goldsmith SR, Gheorghiade M (2011) Tolvaptan for the treatment of heart failure: a review of the literature. Expert Opin Pharmacother 12:961\u2013976","journal-title":"Expert Opin Pharmacother"},{"key":"1270_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000047397","volume":"96","author":"DH Ellison","year":"2001","unstructured":"Ellison DH (2001) Diuretic therapy and resistance in congestive heart failure. Cardiology 96:132\u2013143","journal-title":"Cardiology"},{"key":"1270_CR19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297:1319\u20131331","journal-title":"JAMA"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-018-1270-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-018-1270-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-018-1270-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T14:19:02Z","timestamp":1628605142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-018-1270-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,26]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,15]]}},"alternative-id":["1270"],"URL":"https:\/\/doi.org\/10.1007\/s00380-018-1270-x","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,26]]},"assertion":[{"value":"9 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Takayuki Inomata received lecture honoraria from Otsuka Pharmaceutical Co. and Daiichi-Sankyo Pharmaceutical. Dr. Yugo Shibagaki received lecture honoraria from Otsuka Pharmaceutical and Novartis Pharma; and research funding from Otsuka Pharmaceutical, Teijin Pharma and Kyowa-Hakko Kirin. Dr. Naoki Sato received consultancy fees from Novartis and Terumo; lecture honoraria from Otsuka, Daiichi-Sankyo, Ono, Eisai, Bayer, Boehringer-Ingelheim, Roche Diagnostics-Japan, Astellas, and Teijin; and research supports to institution from Roche-Japan and Astellas. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}